Remote Neuropsychological Testing
Center of Accessible Neuropsychology is researching how different parts of the brain contribute to cognitive processes such as language, mathematics, learning, and emotions. They ask if there is a relationship between cognitive processes and self-reported medical assessment.
Link to enroll: tinyurl.com/yvh2ttdh
About the Study
Eligible Ataxia Types
Spinocerebellar Ataxia and Cerebellar Degeneration (any subtype)
Type of Study
Research Study
Clinical Trial Phase
N/A
Age Range
Children and Adult 18+
Study Start Date
07/07/2023
Estimated Completion Date
07/07/2025
IRB Approval #
0006500-1
Location(s)
Faculty of Medicine, Center for Accessible Neuropsychology
Remote Study
www.sabcan.sites.tau.ac.il/participate
Contact Information
Dr. William Saban
Email: can@tauex.tau.ac.il
What does participation in the study entail?
The study will be conducted online in coordination with the researchers and can be completed from your computer whenever it is convenient for you. The study involves filling out questionnaire/s and performing short tasks, such as pressing buttons in response to stimuli appearing on the computer screen. These tasks can include solving math equations, pressing keys in a specific order, or choosing if a sequence of letters follows a rule or not.
What are the potential benefits for participants?
We hope that this study will prove beneficial by increasing our knowledge of how cognition is processed in the brain.
What are the potential risks for participants?
There are no risks for participants. This research will not interfere with any medical treatment, nor is there any direct benefit to you.
Is there financial compensation?
Yes. $15/hour
Is there travel reimbursement?
No. Not applicable.
Who is eligible?
Spinocerebellar Ataxia and Cerebellar Degeneration (any subtype)
View Other Research Opportunities
Spinocerebellar Ataxia Patient Feedback Survey
The survey aims to gather opinions about Antisense Oligonucleotide (ASO) therapy research, and the information gathered will be used to help develop future clinical studies for ataxia. Link to Enroll: Read More…
PATH
Proactive Approaches to Health for Asymptomatic Adults at Risk for Neurodegenerative Conditions The aim of this study is to assess the needs of asymptomatic adults at-risk to carry a pathogenic Read More…
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy (CYPRESS)
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. This Read More…
